Experimental evaluation of toxic properties of target antitumor drug aimpila

Background. Currently, the drugs, acting directly on tumor molecular or cellular targets, are actively designed. Target antitumor drug aimpila is atractyloside alpha-fetoprotein noncovalent complex. The development of this formulation is based on the ability of alpha-fe-toprotein, as a transport protein, to deliver cytotoxic agents into the cells that have alpha-fetoprotein receptors. Objective: to investigate the toxicity of aimpila in chronic experiment on rabbits. Materials and methods. The study was performed in male and female “Soviet chinchilla” rabbits. Final drug formulation (aimpila in gelatin capsules) was administrated per os at 1 and 10 therapeutic doses (0.05 and 0.5 mg/kg respectively) for 30 days with interval of 24 h. During the study dynamics of body weight, hematological parameters, blood biochemical parameters, electrocardiography and urinalysis were performed for all animals. Five animals in each group were sacrificed in days 1 and 30 post treatment, then their internal organs were subjected to histological evaluation. Results. The study demonstrates that the treatment with aimpila for 30 days in single therapeutic dose of 0.05 mg/kg had no effect on the clinical and laboratory parameters or the morphological structure of the internal organs of rabbits. Signs of hepato-, nephro-, cardio-and gastrointestinal toxicity were found in group of rabbits, treated with high dose of drug. The structural damages in liver were clinically supported with a significant increase of aspartate aminotransferase level in serum. Pathological changes in the kidneys were accompanied by a significant increase of urobilinogen and ketone bodies levels in the urine. Signs of cardio- and gastrointestinal toxicity were documented only by microscopic pathology observation. These abnormalities were reversible within 30 days. Conclusions. Aimpila formulation displayed dose-dependent and reversible toxicity and can be recommended to further investigation.

аимпила, альфа-фетопротеин, атрактилозид, хроническая токсичность, кролики, aimpila, alpha-fetoprotein, atractyloside, chronic toxicity, rabbits

1. Северин С.Е., Москалева Е.Ю., По-сыпанова Г.А. Таргетная терапия рака. Природа 2013; 12: 71 -7.

2. Pak V. The use of a-fetoprotein for the delivery of cytotoxic payloads to cancer cells. Ther Deliv 2014; 5(8): 885-92. DOI: 10.4155/tde.14.59. PMID: 25337646.

3. Posypanova G.A., Gorokhovets N.V., Makarov V.A. et al. Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery. J Drug Target 2008; 16(4): 321-8. PMID: 18446611.

4. Daniele C., Dahamna S., Firuzi O. et. al. Atractylis gummifera L. poisoning: an ethnopharmacological review. J Ethnopharmacol 2005; 97: 175-81. DOI: 10.1016/j.jep.2004.11.025. PMID: 15707749.

5. Obatomi D.K., Bach P.H. Selective cytotoxicity associated with in vitro exposure of fresh rat renal fragments and continuous cell lines to atractyloside. Arch Toxicol 1996; 71(1 -2): 93-8. PMID: 9010590.

6. Stewart M.J., Steenkamp V. The biochemistry and toxicity of atractyloside: a review. Ther Drug Monit 2000; 22(6): 641-9. PMID: 11128230.

7. Council of Europe. European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. ETS 1986: 123.

8. Freireich E.J., Gehan E.A., Rall D.P. et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966; 50(4): 219-44. PMID: 4957125.

9. Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова. Часть I. М.: Гриф и Ко, 2012. С. 13-24.

10. Feldman N.B., Kiselev S.M., Gukasova N.V. et al. Antitumor activity of alpha-fetoprotein conjugate with doxorubicin in vitro and in vivo. Biochemistry 2000; 65(8): 967-71. PMID: 11002192.

11. Nikolskaya E.D., Zhunina O.A., Yabbarov N.G. et al. Development of target delivery system based on actinomycin class drugs and recombinant alpha-feto-protein. Dokl Biochem Biophys 2017; 473(1): 148-50. DOI: 10.1134/S1607672917020156. PMID: 28510139.

12. Barceloux D.G. Medical toxicology of natural substances. Foods, fungi, medicinal herbs, plants and venomous animal. California: John Wiley & Sons, 2008. Pp. 514-517.

13. Черешнев В.А., Родионов С.Ю., Черкасов В.А. и др. Альфа-фетопротеин. Екатеринбург: УрО РАН, 2004. С. 104-129.

14. Obatomi D.K., Thanh N.T., Brant S., Bach P.H. The toxic mechanism and metabolic effects of atractyloside in precision-cut pig kidney and liver slices. Arch Toxicol 1998; 72(8): 524-30. PMID: 9765068.

15. Carpenedo F., Luciani F., Scaravilli F. et al. Nephrotoxic effect of atractyloside in rats. Arch Toxicol 1974; 32(3): 169-80. PMID: 4479740.

16. Hedili A., Warnet J., Thevenin M., Martin C. et.al. Biochemical investigation of Atractylis gummifera L. hepatotoxicyty in the rat. Arch Toxicol Suppl 1989; 13: 312-5. PMID: 2774952.

17. Koechel D.A., Krejci M.E. Extrarenal and direct renal actions of atractyloside contribute to its acute nephrotoxicity in pentobarbital-anesthetized dogs. Toxicology 1993; 79(1): 45-66. PMID: 8475499.

18. Gilmour R.FJr., Williams E.S., Farmer B.B., Zipes D.P. Effects of carnitine and atractyloside on canine cardiac electrical activity. Am J Physiol 1981; 241(4): 505-12. PMID: 7315975.